JP2023551058A5 - - Google Patents
Info
- Publication number
- JP2023551058A5 JP2023551058A5 JP2023533243A JP2023533243A JP2023551058A5 JP 2023551058 A5 JP2023551058 A5 JP 2023551058A5 JP 2023533243 A JP2023533243 A JP 2023533243A JP 2023533243 A JP2023533243 A JP 2023533243A JP 2023551058 A5 JP2023551058 A5 JP 2023551058A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- formula
- acceptable salt
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/108,938 US20220169606A1 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| GB2018955.1 | 2020-12-01 | ||
| US17/108,938 | 2020-12-01 | ||
| GBGB2018955.1A GB202018955D0 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| GB2103981.3A GB2605144A (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| US17/208,583 US11773062B2 (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| GB2103981.3 | 2021-03-22 | ||
| US17/208,583 | 2021-03-22 | ||
| EPPCT/EP2021/060750 | 2021-04-23 | ||
| PCT/EP2021/060750 WO2021116503A2 (en) | 2020-06-02 | 2021-04-23 | Deuterated compounds |
| PCT/EP2021/062794 WO2021244831A1 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| GB2106881.2 | 2021-05-13 | ||
| CA3118556A CA3118556A1 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| EPPCT/EP2021/062794 | 2021-05-13 | ||
| US17/320,155 US12042564B2 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| CA3118556 | 2021-05-13 | ||
| GB2106881.2A GB2595776B (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| US17/320,155 | 2021-05-13 | ||
| PCT/EP2021/082227 WO2022117359A1 (en) | 2020-12-01 | 2021-11-18 | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023551058A JP2023551058A (ja) | 2023-12-06 |
| JP2023551058A5 true JP2023551058A5 (https=) | 2024-11-08 |
| JP7834754B2 JP7834754B2 (ja) | 2026-03-24 |
Family
ID=88294961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533243A Active JP7834754B2 (ja) | 2020-12-01 | 2021-11-18 | 重水素化又は部分重水素化ｎ，ｎ－ジメチルトリプタミン化合物 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP4031529B1 (https=) |
| JP (1) | JP7834754B2 (https=) |
| CN (1) | CN116761599B (https=) |
| AU (1) | AU2021391581A1 (https=) |
| CA (1) | CA3203020A1 (https=) |
| IL (1) | IL303288A (https=) |
| TW (1) | TWI891942B (https=) |
| WO (1) | WO2022117359A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| CA3152752A1 (en) | 2019-10-01 | 2021-04-08 | Thomas Henley | Genetic engineering of fungi to modulate tryptamine expression |
| KR20220082092A (ko) | 2019-11-07 | 2022-06-16 | 스몰 파마 엘티디 | 화합물 |
| KR20220137081A (ko) | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| EP4433049A1 (en) * | 2021-11-18 | 2024-09-25 | Cybin UK Ltd | Injectable and inhalable formulations |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| CN118984868A (zh) | 2021-12-31 | 2024-11-19 | 恩派瑞安神经科学公司 | 用于产生精神药物生物碱的遗传修饰的生物体 |
| EP4463440A1 (en) * | 2022-01-14 | 2024-11-20 | Cybin IRL Limited | Tryptamine compositions and methods |
| US12264131B2 (en) * | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| AU2023361184A1 (en) | 2022-10-13 | 2025-04-24 | Cybin Uk Ltd | Method of administration of a parenteral formulation comprising a psychedelic agent |
| WO2024108195A1 (en) | 2022-11-17 | 2024-05-23 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
| CN121038789A (zh) | 2023-01-23 | 2025-11-28 | 赛本英国有限公司 | 通过肠胃外施用单一有效肠胃外剂量的短效致幻剂治疗精神或神经障碍 |
| CN121194779A (zh) | 2023-03-31 | 2025-12-23 | 赛本英国有限公司 | 包含单胺抗抑郁剂和短效致幻剂的组合 |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2026013174A1 (en) | 2024-07-10 | 2026-01-15 | Cybin Uk Ltd | Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2337507A1 (en) * | 1998-07-16 | 2000-01-27 | Massachusetts Institute Of Technology | Composition for treatment of stress |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| KR20220137081A (ko) * | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| WO2021234608A1 (en) * | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| MX2022014900A (es) * | 2020-06-02 | 2023-03-27 | Small Pharma Ltd | Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada. |
| EP3902541B1 (en) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US11000534B1 (en) * | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2021
- 2021-11-18 EP EP21815486.2A patent/EP4031529B1/en active Active
- 2021-11-18 AU AU2021391581A patent/AU2021391581A1/en active Pending
- 2021-11-18 CA CA3203020A patent/CA3203020A1/en active Pending
- 2021-11-18 WO PCT/EP2021/082227 patent/WO2022117359A1/en not_active Ceased
- 2021-11-18 IL IL303288A patent/IL303288A/en unknown
- 2021-11-18 TW TW110143066A patent/TWI891942B/zh active
- 2021-11-18 JP JP2023533243A patent/JP7834754B2/ja active Active
- 2021-11-18 EP EP23198784.3A patent/EP4275753B1/en active Active
- 2021-11-18 CN CN202180090269.1A patent/CN116761599B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023551058A5 (https=) | ||
| IL303288A (en) | N,N-Dimethyltryptamine compounds partially or fully deuterated | |
| JP2023531311A5 (https=) | ||
| TWI765451B (zh) | 作為erk抑制劑的螺環類化合物及其應用 | |
| JP2022545633A5 (https=) | ||
| JP3262333B2 (ja) | ５−ｈｔ１ａ拮抗物質としてのピペラジン誘導体 | |
| JP2023527575A5 (https=) | ||
| ES2922973T1 (es) | Peptidos funcionalizados como agentes antivirales | |
| JP2005511699A5 (https=) | ||
| JP2005514398A5 (https=) | ||
| WO1993021178A1 (en) | Indole derivatives as 5-ht1-like agonists | |
| JPH0368875B2 (https=) | ||
| CA2632194A1 (en) | N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | |
| JP2008513358A5 (https=) | ||
| JP2006522141A5 (https=) | ||
| JP2006511490A5 (https=) | ||
| JP2023539113A5 (https=) | ||
| ES2377465T3 (es) | Bencilaminas, un proceso para su producción y su uso como agentes anti-inflamatorios | |
| WO2005113537B1 (en) | Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions | |
| RU98102128A (ru) | Производные бензо[g]хинолина | |
| JP2023507774A5 (https=) | ||
| RU2010113358A (ru) | Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов | |
| JP2023542945A5 (https=) | ||
| JPH0276851A (ja) | ピペリジン誘導体 | |
| JP2007522111A5 (https=) |